Jack Davis

Biography

Jack Davis is Director and Chairman, BioMarker Strategies. He brings more than forty years of experience forming and leading companies in the molecular diagnostics, pathology, and clinical laboratory industries. Mr. Davis has a track record of success bringing breakthrough technologies and tests to the market for the benefit of cancer patients. Mr. Davis’ professional career includes serving as a co-founder, President/COO and later CEO, and Chairman of Dianon Systems, Inc., which he helped build from a venture capital backed start-up to a leading provider of Clinical and Anatomic Pathology based solutions for clinicians. Dianon was purchased by LabCorp in 2003 for $600 m. In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO. Previously, he was the Division Vice President and General Manager of the $100 m worldwide Diagnostic Products business unit of Abbott Diagnostics. Mr. Davis has also served on the Board of Directors of over twelve companies, including HistoRx, RedPath Integrated Pathology and Asterand. Over the course of his career, he has taken two companies public as CEO and sold three other companies as either Chairman or Director.

Research Interest

  BioMarker Strategies has developed the proprietary and recently patented SnapPath Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies.